Prasco & Eli Lilly Sign Agreement for Generics

Prasco Laboratories and Eli Lilly have signed a marketing and distribution agreement for two generic products in the U.S. market.

Ohio-based privately held healthcare company Prasco Laboratories announced Thursday its marketing and distribution agreement with Eli Lilly and Company to market the Authorized Generic version of ZYPREXA (olanzapine) Tablets and ZYPREXA ZYDIS (olanzapine) Orally Disintegrating Tablets, in the U.S.

Prasco will begin distribution of both products upon the first ANDA entrant into the market. Prasco will market all six strengths of Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg. Olanzapine Orally Disintegrating Tablets will be available in 5 mg, 10 mg, 15 mg, and 20 mg strengths.

Olanzapine Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA. Olanzapine Orally Disintegrating Tablets are therapeutically equivalent